Alkermes’ ALKS 2680 improves wakefulness in Phase 1b narcolepsy study

Alkermes announced positive topline results from the narcolepsy type 2 – NT2 – and idiopathic hypersomnia – IH – cohorts of a phase 1b, proof-of-concept study evaluating ALKS 2680, the company’s novel, investigational, oral orexin 2 receptor agonist in development as a once-daily treatment for narcolepsy. ALKS 2680 data demonstrated clinically meaningful and statistically significant improvements from baseline in mean sleep latency on the Maintenance of Wakefulness Test vs. placebo at all doses tested. ALKS 2680 was generally well tolerated in both patient populations at all doses tested. The company plans to initiate a phase 2 study in patients with NT2 in the second half of 2024. Alkermes expects to submit results from this phase 1b, proof-of-concept study to a peer-reviewed journal for publication and to present additional ALKS 2680 study results at upcoming scientific meetings.